RxDoctor Payments DataLook up a doctor →

Roger Laham, MD

Interventional Cardiology · Boston, MANPI 1184680860

Payments from drug & device makers

$1,182,340in general payments, 2019–2025

Across 342 payments — averaging $3457.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$673K
  • Abbott$300K
  • Medtronic$195K
  • Boston Scientific$13K
  • Siemens Medical Solutions USA, Inc.$1K
  • Ancora Heart, Inc.$604
  • plus $215 from 3 others

What the payments were for

  • Consulting fees$12,29413%
  • Speaking & faculty fees$62,30667%
  • Travel & lodging$9,24010%
  • Food & beverage$9,10810%
  • Education$1260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Edwards Lifesciences98$672,522
Abbott114$299,769
Medtronic(2 entities)97$195,271
Boston Scientific14$12,717
Siemens Medical Solutions USA, Inc.8$1,242
Ancora Heart, Inc.4$604
Abiomed4$125
Heartflow, Inc.2$65
Cathworks, Inc.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,182,340 in reported general payments places this provider in the 90th percentile of 128 interventional cardiology providers in Massachusetts.

See all interventional cardiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$212,242
Medicare patients
502
Services billed
943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin11$6,688
Metoprolol Succinate34$725
Atorvastatin Calcium29$436
ClopidogrelClopidogrel Bisulfate18$272
Lisinopril19$190
Amlodipine Besylate15$128

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →